Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Inflammatory cytokines TNF-α and IL-17 enhance the efficacy of cystic fibrosis transmembrane conductance regulator modulators
Tayyab Rehman, … , Pradeep K. Singh, Michael J. Welsh
Tayyab Rehman, … , Pradeep K. Singh, Michael J. Welsh
Published June 24, 2021
Citation Information: J Clin Invest. 2021;131(16):e150398. https://doi.org/10.1172/JCI150398.
View: Text | PDF
Research Article Pulmonology

Inflammatory cytokines TNF-α and IL-17 enhance the efficacy of cystic fibrosis transmembrane conductance regulator modulators

  • Text
  • PDF
Abstract

Without cystic fibrosis transmembrane conductance regulator–mediated (CFTR-mediated) HCO3– secretion, airway epithelia of newborns with cystic fibrosis (CF) produce an abnormally acidic airway surface liquid (ASL), and the decreased pH impairs respiratory host defenses. However, within a few months of birth, ASL pH increases to match that in non-CF airways. Although the physiological basis for the increase is unknown, this time course matches the development of inflammation in CF airways. To learn whether inflammation alters CF ASL pH, we treated CF epithelia with TNF-α and IL-17 (TNF-α+IL-17), 2 inflammatory cytokines that are elevated in CF airways. TNF-α+IL-17 markedly increased ASL pH by upregulating pendrin, an apical Cl–/HCO3– exchanger. Moreover, when CF epithelia were exposed to TNF-α+IL-17, clinically approved CFTR modulators further alkalinized ASL pH. As predicted by these results, in vivo data revealed a positive correlation between airway inflammation and CFTR modulator–induced improvement in lung function. These findings suggest that inflammation is a key regulator of HCO3– secretion in CF airways. Thus, they explain earlier observations that ASL pH increases after birth and indicate that, for similar levels of inflammation, the pH of CF ASL is abnormally acidic. These results also suggest that a non-cell-autonomous mechanism, airway inflammation, is an important determinant of the response to CFTR modulators.

Authors

Tayyab Rehman, Philip H. Karp, Ping Tan, Brian J. Goodell, Alejandro A. Pezzulo, Andrew L. Thurman, Ian M. Thornell, Samantha L. Durfey, Michael E. Duffey, David A. Stoltz, Edward F. McKone, Pradeep K. Singh, Michael J. Welsh

×

Figure 9

Airway inflammation correlates with ivacaftor-induced lung function improvements.

Options: View larger image (or click on image) Download as PowerPoint
Airway inflammation correlates with ivacaftor-induced lung function impr...
Induced sputum samples were obtained from individuals with CF with a CFTR-G551D or a CFTR-R117H mutation immediately before starting ivacaftor. Sputum inflammatory markers IL-1β, IL-8, and neutrophil elastase (NE) were measured using ELISA. Lung function was evaluated immediately before and 2 days after starting ivacaftor. Data are from previously reported studies (15, 45, 53). (A–D) Relationship between baseline airway inflammation and changes in lung function, measured as %(ΔppFEV1/ppFEV1) where ppFEV1 is the percentage predicted forced expiratory volume in 1 second (n = 23). (E) Changes in IL8 and IL1B gene expression in human CF airway epithelia treated with TNF-α+IL-17 for 48 hours (n = 5 different donors). (F) Relationship between baseline airway inflammation and changes in sweat Cl– concentration 2 days after starting ivacaftor (n = 22). Statistical significance was tested using Pearson’s r test for A–D and F and paired Student’s t test for E. Bars in E indicate mean ± SEM. *P < 0.05, ****P < 0.0001.

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts